All In Biotech

Drug Trial Radar · NCT05380882

Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers

A Phase I Study of TQB2930 Injection in Patients With Advanced Cancers

Last checked: Nov 19, 2026Latest source record: May 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

May 2022

Primary completion

Apr 2023

Study completion Dec 2023

Sponsor

Sponsor type
Industry
First posted
May 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQB2930 is an anti-HER2 (Human Epidermal Growth Factor Receptor 2) bispecific antibody that can simultaneously bind two epitopes of HER2, leading to a dual HER2 signal blockage. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB2930 injection in subjects with advanced malignancies.

Conditions

  • Advanced Cancers

Interventions

  • TQB2930 injectionDrug

    TQB2930 is an anti-HER2 bispecific antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 or 28 days)
  2. Maximum tolerated dose (MTD)Time frame: At the end of Cycle 1 (each cycle is 21 or 28 days).
  3. Adverse events (AE) rateTime frame: From date of the first dose until the date of 28 days after last dose or new anti-tumor treatment, whichever came first.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.